Bypassing pre-existing antibodies extends the applicability of AAV-based retinal therapies

Hannah F Hu¹, Stephen H Tsang²

• ¹Department of Biomedical Engineering, Columbia University, New York, NY, USA; Jonas Children's Vision Care (JCVC), Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, USA; Departments of Ophthalmology, Pathology & Cell Biology, Vagelos College of Physicians and Surgeons, Institute of Human Nutrition, Columbia Stem Cell Initiative, New York, NY, USA.+1